SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004619
Filing Date
2024-02-01
Accepted
2024-02-01 17:00:41
Documents
18
Period of Report
2024-01-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48210
2 ex4-1.htm EX-4.1 79184
3 ex10-1.htm EX-10.1 86676
4 ex10-2.htm EX-10.2 39930
  Complete submission text file 0001493152-24-004619.txt   515605

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cldi-20240126.xsd EX-101.SCH 3813
6 XBRL DEFINITION FILE cldi-20240126_def.xml EX-101.DEF 26683
7 XBRL LABEL FILE cldi-20240126_lab.xml EX-101.LAB 36833
8 XBRL PRESENTATION FILE cldi-20240126_pre.xml EX-101.PRE 25307
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5925
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24587769
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)